E-ISSN 2231-3206 | ISSN 2320-4672
 

Original Research 


Comparative evaluation of cost-effectiveness of alpha blockers prescribed in patients with non-neurogenic lower urinary tract symptoms due to benign prostatic hyperplasia

Shikha Dwivedi, Vimal Kumar Dixit, Shalu Bawa, Mirza Atif Beg, Dilip Chandra Dhasmana.

Abstract
Background: Lower urinary tract symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH) is a common problem among aging men. Several classes of drugs are efficacious and safe, but the first-line treatment is with alpha-1 adrenergic blockers. They provide symptomatic relief and have to be taken for a longer duration to sustain the effect. The preferred alpha-blockers among the stockpile should be efficacious, tolerable, and also cost-effective.

Aim and Objective: This study focuses to compare the cost-effectiveness of various alpha blockers prescribed in patients with LUTS-BPH.

Materials and Methods: An observational study of 78 patients who were newly diagnosed with LUTS-BPH from April 2014 to May 2015 was conducted. Patients were followed up at 4 weeks and at 12 weeks after the drugs had been prescribed. Efficacy assessment was done on basis of change in International Prostate Symptom Score (IPSS) score over 12 weeks. Average cost-effectiveness ratio of different alpha-blockers prescribed was evaluated and compared with Mann-Whitney U test in order to find the most cost-effective alpha-blocker in the study.

Results: All patients were prescribed alpha-blockers either alone or in combination with other drugs. Tamsulosin was prescribed to n = 46, Silodosin to n = 16 and Alfuzosin to n = 16. The efficacy in terms of Mean change in IPSS after 12 weeks of study was 11.34 ± 5.23 for Tamsulosin, 11.70 ± 5.9 for Silodosin and 10.87 ± 4.77 for Alfuzosin and average cost-effectiveness ratio was 108.74, 183.07 and 127.50 for Tamsulosin, Silodosin, and Alfuzosin, respectively.

Conclusion: Tamsulosin was the most cost-effective drug among the prescribed alpha-blockers. Since all the prescribed alpha-blockers had comparable efficacy so we concluded that the most cost-effective drug should be preferred for long-duration treatment.

Key words: Alpha Blockers; Tamsulosin; Silodosin; Alfuzosin; Cost-effectiveness; Lower urinary tract symptom-Benign Prostatic Hyperplasia


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Shikha Dwivedi
Articles by Vimal Kumar Dixit
Articles by Shalu Bawa
Articles by Mirza Atif Beg
Articles by Dilip Chandra Dhasmana
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Dwivedi S, Dixit VK, Bawa S, Beg MA, Dhasmana DC. Comparative evaluation of cost-effectiveness of alpha blockers prescribed in patients with non-neurogenic lower urinary tract symptoms due to benign prostatic hyperplasia. Natl J Physiol Pharm Pharmacol. 2022; 12(5): 588-591. doi:10.5455/njppp.2022.12.10359202126102021


Web Style

Dwivedi S, Dixit VK, Bawa S, Beg MA, Dhasmana DC. Comparative evaluation of cost-effectiveness of alpha blockers prescribed in patients with non-neurogenic lower urinary tract symptoms due to benign prostatic hyperplasia. https://www.njppp.com/?mno=84968 [Access: May 02, 2022]. doi:10.5455/njppp.2022.12.10359202126102021


AMA (American Medical Association) Style

Dwivedi S, Dixit VK, Bawa S, Beg MA, Dhasmana DC. Comparative evaluation of cost-effectiveness of alpha blockers prescribed in patients with non-neurogenic lower urinary tract symptoms due to benign prostatic hyperplasia. Natl J Physiol Pharm Pharmacol. 2022; 12(5): 588-591. doi:10.5455/njppp.2022.12.10359202126102021



Vancouver/ICMJE Style

Dwivedi S, Dixit VK, Bawa S, Beg MA, Dhasmana DC. Comparative evaluation of cost-effectiveness of alpha blockers prescribed in patients with non-neurogenic lower urinary tract symptoms due to benign prostatic hyperplasia. Natl J Physiol Pharm Pharmacol. (2022), [cited May 02, 2022]; 12(5): 588-591. doi:10.5455/njppp.2022.12.10359202126102021



Harvard Style

Dwivedi, S., Dixit, . V. K., Bawa, . S., Beg, . M. A. & Dhasmana, . D. C. (2022) Comparative evaluation of cost-effectiveness of alpha blockers prescribed in patients with non-neurogenic lower urinary tract symptoms due to benign prostatic hyperplasia. Natl J Physiol Pharm Pharmacol, 12 (5), 588-591. doi:10.5455/njppp.2022.12.10359202126102021



Turabian Style

Dwivedi, Shikha, Vimal Kumar Dixit, Shalu Bawa, Mirza Atif Beg, and Dilip Chandra Dhasmana. 2022. Comparative evaluation of cost-effectiveness of alpha blockers prescribed in patients with non-neurogenic lower urinary tract symptoms due to benign prostatic hyperplasia. National Journal of Physiology, Pharmacy and Pharmacology, 12 (5), 588-591. doi:10.5455/njppp.2022.12.10359202126102021



Chicago Style

Dwivedi, Shikha, Vimal Kumar Dixit, Shalu Bawa, Mirza Atif Beg, and Dilip Chandra Dhasmana. "Comparative evaluation of cost-effectiveness of alpha blockers prescribed in patients with non-neurogenic lower urinary tract symptoms due to benign prostatic hyperplasia." National Journal of Physiology, Pharmacy and Pharmacology 12 (2022), 588-591. doi:10.5455/njppp.2022.12.10359202126102021



MLA (The Modern Language Association) Style

Dwivedi, Shikha, Vimal Kumar Dixit, Shalu Bawa, Mirza Atif Beg, and Dilip Chandra Dhasmana. "Comparative evaluation of cost-effectiveness of alpha blockers prescribed in patients with non-neurogenic lower urinary tract symptoms due to benign prostatic hyperplasia." National Journal of Physiology, Pharmacy and Pharmacology 12.5 (2022), 588-591. Print. doi:10.5455/njppp.2022.12.10359202126102021



APA (American Psychological Association) Style

Dwivedi, S., Dixit, . V. K., Bawa, . S., Beg, . M. A. & Dhasmana, . D. C. (2022) Comparative evaluation of cost-effectiveness of alpha blockers prescribed in patients with non-neurogenic lower urinary tract symptoms due to benign prostatic hyperplasia. National Journal of Physiology, Pharmacy and Pharmacology, 12 (5), 588-591. doi:10.5455/njppp.2022.12.10359202126102021